chufangao/CTO huggingface dataset:
Clinical trial NCT03308565: Adipose Stem Cells for Traumatic Spinal Cord Injury
Official title: Phase I Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury
Acronym: CELLTOP
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-05
Primary completion date: 2019-10-22
Completion date: 2021-10-11
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04537806: A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Official title: A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
Sponsor: Sage Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Internal company decision
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-18
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Baseline population: FAS included all randomized participants who initiated IP (brexanolone or placebo).
Limitations and caveats: The study was terminated early due to sponsor's decision and there were no safety concerns.
Plan to share individual participant data: NO
IPD sharing description: Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Clinical trial NCT05709821: IMM60 and Pembrolizumab in Melanoma and NSCLC
Official title: IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC
Sponsor: Portage Biotech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Prioritization of other pipeline assets. No safety or efficacy issues were observed.
Enrollment: 1.0 (ACTUAL)
Number of arms: 6.0
Start date: 2023-11-15
Primary completion date: 2024-04-22
Completion date: 2024-04-22
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03592641: Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
Official title: A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inadequate accrual rate
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-25
Primary completion date: 2021-07-31
Completion date: 2021-12-30
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Clinical trial NCT04991350: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
Official title: Comparison of the Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Using OCTA
Acronym: REBEL
Sponsor: Cairo University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Insufficient recruitment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-26
Primary completion date: 2022-09-01
Completion date: 2022-11-01
Plan to share individual participant data: NO
Clinical trial NCT03919045: Saline Injections for Prophylactic Treatment of Chronic Migraine
Official title: Saline Injections for Prophylactic Treatment of Chronic Migraine - a Randomized Controlled Study
Sponsor: Göteborg University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to Covid-19 the rehabilitation unit where the trial was conducted were closed and the trial active clinician had to work at the hospital intensive care.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-17
Primary completion date: 2021-05-21
Completion date: 2021-05-21
Plan to share individual participant data: NO
Clinical trial NCT04688164: A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
Acronym: Reliance I
Sponsor: Relmada Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 227.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-08
Primary completion date: 2022-11-01
Completion date: 2022-11-10
Clinical trial NCT05554679: Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women .
Official title: Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women a Randomized Control Trial.
Sponsor: Assiut University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: financial issues
Enrollment: 178.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2022-12-30
Completion date: 2023-07-11
Clinical trial NCT05042362: A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Official title: A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
Acronym: OASIS-1
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 396.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-27
Primary completion date: 2023-07-25
Completion date: 2023-11-27
Plan to share individual participant data: NO
Clinical trial NCT01815580: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
Official title: HIV Testing and Treatment to Prevent Onward HIV Transmission Among MSM and Transgender Women in Lima, Peru
Acronym: SABES?
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 225.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-07-31
Primary completion date: 2020-11-30
Completion date: 2021-06-30
Baseline population: 5 participants from the Immediate arm and 4 participants from the Deferred arm were excluded from the analyses because by the time they were enrolled they could no longer be considered Acute or Recent HIV infection.
Plan to share individual participant data: NO
Clinical trial NCT05227209: A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
Official title: A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Company decided not to move forward with further accrual.
Enrollment: 64.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-17
Primary completion date: 2023-11-17
Completion date: 2023-11-17
Plan to share individual participant data: YES
IPD sharing description: IPD for this study may be made available upon request via theVivli Center for Global Clinical Reserach Data site
IPD time frame: IPD will be made available upon request within 12 months of posting the study results on ct.gov.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT05254613: A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of Subcutaneous ALXN1830 in Healthy Participants
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The justification of the early termination of the trial: the study is early terminated due to the Coronavirus 2019 epidemic.
Enrollment: 12.0 (ACTUAL)
Number of arms: 7.0
Start date: 2019-11-12
Primary completion date: 2021-01-22
Completion date: 2021-01-22
Baseline population: The safety population consisted of all participants who received at least 1 dose of study drug.
Limitations and caveats: The study was terminated early due to a lack of participant availability caused by COVID-19 pandemic after completion of the ALXN1830 750 mg dose group and partial enrollment of the ALXN1830 1250 mg dose group.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03653026: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis
Acronym: U-Accomplish
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 522.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-06
Primary completion date: 2021-01-14
Completion date: 2021-01-14
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04653142: A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)
Official title: An Open Label, Phase I Study of BI 765063 Monotherapy, and Its Combination Therapy With BI 754091, to Characterize Safety, Pharmacokinetics, and Pharmacodynamics in Japanese Patients With Advanced Solid Tumors
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-15
Primary completion date: 2022-04-20
Completion date: 2022-04-20
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datasharing
Clinical trial NCT04786964: Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer
Official title: A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer
Acronym: CONTERNO
Sponsor: Checkpoint Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Regional political conflict
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-08
Primary completion date: 2023-12-30
Completion date: 2023-12-30
Clinical trial NCT06377722: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Official title: Phase II Study for the Evaluation of Neoadjuvant Treatment With Cabozantinib Pior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Sponsor: Fundacion Oncosur (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive final result analysis was conducted, as presented herein.
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-01
Primary completion date: 2022-08-09
Completion date: 2022-08-09
Clinical trial NCT02284737: A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
Official title: A Prospective, Multi-center, Randomized Control Trial to Investigate the Efficacy of Pulmonary Artery Denervation to Improved Functional Capacity and Hemodynamics in Patients With Pulmonary Artery Hypertension
Acronym: PADN-PAH
Sponsor: Nanjing First Hospital, Nanjing Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of subjects.
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-11-28
Primary completion date: 2021-07-30
Completion date: 2021-07-30
Plan to share individual participant data: NO
Clinical trial NCT04150562: Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Official title: Phase II Trial of Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-26
Primary completion date: 2021-07-23
Completion date: 2021-09-16
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request.
IPD time frame: Clinical data will be available during the study and indefinitely.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).
Clinical trial NCT05256810: A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
Official title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout
Sponsor: Alnylam Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The Sponsor elected not to continue with the study
Enrollment: 44.0 (ACTUAL)
Number of arms: 7.0
Start date: 2022-02-25
Primary completion date: 2023-01-25
Completion date: 2023-01-25
Plan to share individual participant data: NO
Clinical trial NCT04486313: Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Official title: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Sponsor: Romark Laboratories L.C. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 935.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-13
Primary completion date: 2021-02-08
Completion date: 2021-02-08
Clinical trial NCT05414864: Insomnia Prevalence and Treatment Impact on Systemic Hypertension
Official title: Insomnia Prevalence and Treatment Impact on Systemic Hypertension
Acronym: Print-HAS
Sponsor: University of Sao Paulo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Takeda suspended financial support. The first phase (observational study) is ongoing.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-01
Primary completion date: 2022-07-31
Completion date: 2022-09-30
Clinical trial NCT03965624: Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
Official title: A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia
Acronym: Ixa-Cyto
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Decision of sponsor: impossibility of contract with Takeda
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-01
Primary completion date: 2023-03-01
Completion date: 2023-09-01
Plan to share individual participant data: NO
IPD sharing description: DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
Clinical trial NCT03575598: Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
Official title: Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
Acronym: SNOW
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-30
Primary completion date: 2020-02-18
Completion date: 2020-02-18
Plan to share individual participant data: NO
Clinical trial NCT01143545: Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Official title: Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2010-12-07
Primary completion date: 2015-02-09
Completion date: 2020-02-26
Clinical trial NCT02892201: Pembrolizumab in HNSCC With Residual Disease After Radiation
Official title: A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-08
Primary completion date: 2020-02-29
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT02740270: Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
Official title: A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-22
Primary completion date: 2020-03-03
Completion date: 2020-03-03
Plan to share individual participant data: NO
Clinical trial NCT03544229: A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 242.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-10-14
Primary completion date: 2021-06-14
Completion date: 2021-07-15
Baseline population: Randomized Set included all participants who were randomized.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04059406: Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
Official title: A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients With Non-Transfusion Dependent β-Thalassemia Intermedia
Sponsor: Ionis Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Favorable safety and tolerability were seen, but efficacy results in the mid-stage study did not meet Ionis' minimum target product profile to justify further development.
Enrollment: 29.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-24
Primary completion date: 2023-03-28
Completion date: 2023-03-28
Plan to share individual participant data: NO
Clinical trial NCT05387577: Coagulation and Fibrinolysis of Estradiol in Transwomen
Official title: Coagulation Activation and Fibrinolysis With Sublingual Versus Oral Versus Transdermal Estradiol in Transgender Women
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: per MCW IRB
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-07
Primary completion date: 2022-11-23
Completion date: 2022-11-23
Plan to share individual participant data: YES
IPD sharing description: All individual participant data that underlie results in a publication.
IPD time frame: starting 3 months after publication
IPD access criteria: IPD will be shared if PI is directly contacted and asked for the above information.